We are live on ! Find out more

2,353 hedge funds and large institutions have $100B invested in Amgen in 2022 Q2 according to their latest regulatory filings, with 133 funds opening new positions, 927 increasing their positions, 925 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more funds holding in top 10

Funds holding in top 10: 5193 (+42)

60% more first-time investments, than exits

New positions opened: 133 | Existing positions closed: 83

1.37% more ownership

Funds ownership: 76.08%77.45% (+1.4%)

1% more funds holding

Funds holding: 2,3382,353 (+15)

0% more repeat investments, than reductions

Existing positions increased: 927 | Existing positions reduced: 925

2% less capital invested

Capital invested by funds: $102B → $100B (-$1.54B)

18% less call options, than puts

Call options by funds: $1.68B | Put options by funds: $2.05B

Holders
2,353
Holders Change
+15
Holders Change %
+0.64%
% of All Funds
39.63%
Holding in Top 10
93
Holding in Top 10 Change
+42
Holding in Top 10 Change %
+82.35%
% of All Funds
1.57%
New
133
Increased
927
Reduced
925
Closed
83
Calls
$1.68B
Puts
$2.05B
Net Calls
-$373M
Net Calls Change
-$272M

AMGN Hedge Fund Activity: Q2 2022 in Review

2,353 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Amgen (AMGN) for Q2 2022, worth a combined $100B — down 1.5% from $102B a quarter earlier.

Buyers outnumbered sellers: 133 funds opened new AMGN positions and 83 closed out — a net gain of 50 holders — while 927 added to existing stakes and 925 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $1.09B. The largest seller was Capital Research Global Investors, cutting an estimated $1.06B.

  • 2,353 institutional investors held Amgen (AMGN) as of Q2 2022, up from 2,338 in Q1 2022.
  • Funds reported $100B of Amgen stock for Q2 2022, down 1.5% quarter-over-quarter.
  • 133 funds opened new Amgen positions in Q2 2022 and 83 closed out, a net change of +50 holders.
  • The largest Amgen buyer in Q2 2022 was Goldman Sachs, an estimated $1.09B added.
  • The largest Amgen seller in Q2 2022 was Capital Research Global Investors, an estimated $1.06B sold.

Based on aggregated 13F filings for Q2 2022.